Glycans as a target in the detection of reproductive tract cancers

Journal of Medical Biochemistry

Volumn 27, Issue 1, 2008, Pages 17-29

  Janković, Miroslava ^a,b   Kosanović, Maja ^a   Milutinović, Bojana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INEP ^*  (Serbia)

Author keywords

CA125; Glycosylation; Ovary; Prostate; PSA; Tumor marker

Indexed keywords

CA 125 ANTIGEN; GLYCAN; LECTIN; OLIGOSACCHARIDE; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; BENIGN TUMOR; CANCER DIAGNOSIS; CARBOHYDRATE ANALYSIS; CHEMICAL MODIFICATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FUCOSYLATION; GLYCOSYLATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; OVARY CANCER; PROSTATE CANCER; PROSTATE CARCINOMA; PUBLICATION; REVIEW; SIALYLATION;

EID: 41849133570     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-007-0041-5     Document Type: Review

References (107)

1. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochem Biophys Acta 1999; 1473: 4-8.
2. Sharon N, Lis H. Glycoproteins: Structure and function. In: Gabius HJ, Gabius S, eds. Glycoscience: status and perspectives. Weinheim: Chapman & Hall; 1997: 133-54.
3. Taylor M, Drickammer C. Introduction to glycobiology. Oxford University Press, 2003.
4. Laine RA. The information-storing potential of the sugar code. In: Gabius HJ, Gabius S, eds. Glycoscience: status and perspectives. London: Chapman & Hall; 1997: 1-14.
5. Gabius HJ, Andre S, Kaltner H, Siebert HC. The sugar code: functional lectinomics. Biochem Biophys Acta 2002; 1572: 165-77.
6. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 2004; 14 (11): 53-62.
7. Gagneux P, Varki A. Evolutionary consideration in relating oligosaccharide diversity to biological function. Glycobiology 1999; 9 (8): 747-55.
8. Kilpatrick DC. Animal lectins: a historical overview. Biochem Biophys Acta 2002; 1572: 187-97.
9. Janković M, Čuperlović M. Animal soluble beta galactoside binding lectins-galectins. A review. Arch Biol Sci 1996; 48 (3-4): 65-77.
10. Janković M, Čuperlović M. Carbohydrate-binding and carbohydrate-containing nuclear proteins. Review, Iugoslav Physiol Pharmacol Acta 1993; 29 (2): 121-8.
11. Spiro R. Protein glycosylation: nature, distribution, enzymatic formation, and disease implication of glycopeptide bonds. Glycobiology 2002; 12 (4): 43-56.
12. Brockhausen I, Kuhns W, eds. Glycoproteins and Human Disease. Heidelberg: Medical Intelligence Unit, Springer; 1997.
13. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochem Biophys Acta 1999; 1473: 67-95.
14. Dennis JW, Granovsky M, Warren C. Glycoprotein glycosylation and cancer progression. Biochem Biophys Acta 1999; 1473: 21-34.
15. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95 (5): 377-84.
16. Danishefsky SJ, Allen JR. From the laboratory to the clinic: a retrospective of the fully synthetic carbohydrate-based anticancer vaccines. Angew Chem Int Ed Eng 2000; 39: 836-63.
17. Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cell, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83: 429-39.
18. Fukuda M. Cell surface carbohydrates: cell type-specific expression. In: Fukuda M, Hindsgaul O, eds. Molecular and Cellular Glycobiology. Oxford: Oxford University Press; 2000: 1-61.
19. Nikolić JA, Janković M. Purification of human alpha fetoprotein. J Serb Chem Soc 1994; 59 (8): 525-30.
20. Savin S, Cvejić D, Janković M. Expression of galectin-1 and galectin-3 in human fetal thyroid gland. J Histochem Cytochem 2003; 51 (4): 479-83.
21. Golubović S, Janković Lj, Movsesijan A, Bojić Ž, Janković M. Salivary carcinoembryonic antigen as inflammatory marker. Jugoslov Med Biohem 2003; 22 (83): 207-11.
22. Golubović S, Janković M. Glycobiochemical characterization of salivary carcinoembryonic antigen. J.B.U.ON. 2007; 12: 269-75.
23. Davis B. Recent developments in glycoconjugates. J Chem Soc Perkin Trans 1999; 1: 3215-7.
24. Koeller KM, Wong CH. Emerging themes in medicinal glycoscience. Nat Biotechnol 2000; 18 (8): 835-41.
25. Makker PN, Conklin J, Hogan V, Raz A. Carbohydrate-binding proteins in cancer and their ligands as therapeutic agents. Trends Mol Med 2002; 8 (4): 187-92.
26. Macmillian D, Daines AM. Recent developments in the synthesis and discovery of oligosaccharides and glycoconjugates for the treatment of disease. Current Med Chem 2003; 10: 2733-73.
27. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257-331.
28. Yarema KJ, Bertozzi CR. Characterizing glycosylation pathways. Genome Biology 2001; 2 (5): 0004.1-10.
29. Guo HB, Yhang QS, Chen HL. Effects of H-ras and V-sis overexpression on N-acetylglucosaminyltransferase V and metastasis-related phenotypes in human hepatocarcinoma cells. J Cancer Res Clin Oncol 2000; 26: 263-70.
30. Brockhausen I, Schatner H. Glycosyltransferases involved in N- and O-Glycan Biosynthesis. In: Gabius HJ, Gabius S, eds. Glycoscience: status and perspectives. London: Chapman & Hall; 1997: 79-115.
31. Ogata S, Muramatsu T, Kobata A. New structural characteristics of the large glycopeptides from transformed cells. Nature 1976; 235: 275-8.
32. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. β1-6 branching of asn-linked oligosaccharides directly associated with metastasis. Science 1987; 236: 582-5.
33. Miyagi T, Wada T, Yamaguchi K, Hata K. Sialidase and malignancy: a minireview. Glycoconj J 2004; 20 (3): 189-98.
34. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001; 18 (11-12): 841-50.
35. Dall'Olio F. The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role. Glycoconj J 2000; 17 (10): 669-76.
36. Yazawa S, Madiyalakan R, Izawa H, Asao T, Furukawa K, Matta KL. Cancer-associated elevation of alpha(1-3)-L-fucosyltransferase activity in human serum. Cancer 1988; 62 (3): 516-20.
37. Asao T, Kuwano H, Nakamura J, Okamura A, Berger EG, Matta KL, et al. Tumor cells as the origin of elevated serum alpha1,3fucosyltransferase in association with malignancy. Clin Exp Metastasis 2000; 18 (7): 605-10.
38. Yuriev E, Farrugia W, Scott AM, Ramsland PA. Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol 2005; 83 (6): 709-17.
39. Lewis JD, Reilly BD, Bright RK. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003; 22 (2): 81-112.
40. Desai PR. Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med Rev 2000; 14 (4): 312-25.
41. Kobayashi H, Terao H, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10: 95-101.
42. Metoki R, Kakudo K, Tsuji Y, Theng N, Clausen H, Hakomori S. Deletion of histo-blood group A and B antigens and expression of incompatible A antigen in ovarian cancer. J Natl Cancer Inst 1989; 81 (15): 1151-7.
43. Podolsky DK, Weiser MM, Isselbacher KJ, Cohen AM. A cancer-associated galactosyltransferase isoenzyme. N Engl J Med 1978, 299: 703-5.
44. Podolsky DK, Weiser MM. Purification of galactosyltransferase »isoenzymes« I and II. Comparison of cancer-associated and normal galactosyltransferase activities. J Biol Chem 1979; 254 (10): 3983-90.
45. Brockhausen I, Kuhns W. Cancer of the Urinary and Reproductive tracts. In: Brockhausen I, Kuhns W, eds. Glycoproteins and Human Disease. Heidelberg: Medical Intelligence Unit, Springer; 1997: 201-6.
46. Arenas M, Romo E, De Gaspar I, De Bethencourt FR, Sanchez-Chapado M, Benito F, et al. A lectin histochemistry comparative study in human normal prostate, benign prostatic hyperplasia, and prostate cancer. Glycoconj J 1999; 16: 375-82.
47. Chan FL, Choi HL, Ho SM. Analysis of glycoconjugate patterns of normal and hormone-induced dysplastic Noble rat prostates, and an androgen-independent Noble rat prostate tumor, by lectin histochemistry and blotting. Prostate 2001; 46 (1): 21-32.
48. Abel PD, Foster CS, Tebbutt S, Williams G. Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. J Urol 1990; 144 (3): 760-5.
49. Chandarsekaran EV, Chawda R, Locke RD, Piskorz CF, Matta KL. Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alpha1,2-L-fucosyltransferase. Glycobiology 2002; 12 (3): 153-62.
50. Martensson S, Bigler SA, Brown M, Lange PH, Brawer MK, Hakomori S. Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. Hum Pathol 1995; 26 (7): 735-9.
51. Jorgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55(9): 1817-9.
52. Jenis DM, Basu S, Pollard M. Increased activity of a beta- galactosyltransferase in tissues of rats bearing prostate and mammary adenocarcinomas. Cancer Biochem Biophys 1982; 6: 37-45.
53. Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Egawa S, et al. Changes in IgG oligosaccharide chains with prostate cancer progression. Anticancer Res 2004; 24 (5B): 3135-9.
54. Troyer DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis. Disease Markers 2004; 20(2): 117-28.
55. Stephan C, Jung K, Diamandis E, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002; 59: 2-8.
56. Belanger A, Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate-specific antigen: studies for establishment of an international PSA standard. Prostate 1995; 27: 187-97.
57. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in seminal fluid. Clin Chem 1995; 41 (11): 1567-73.
58. Huber PR, Schimid HP, Mattarelli G, Strittmatter B, Van Steenburg GJ, Maurer A. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995; 27: 212-9.
59. Hilz H, Noldus J, Hammerer P, Buck F, Luck M, Hulan H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 1999; 36: 286-92.
60. Donohue MJ, Satterfield MB, Dalluge JJ, Welch MJ, Girard JE, Bunk DM. Capillary electrophoresis for the investigation of prostate-specific antigen heterogeneity. Anal Biochem 2005; 339 (2): 318-27.
61. Prakash S, Robbins PW. Glycotyping of prostate specific antigen. Glycobiology 2000; 10: 173-6.
62. Okada T, Sato Y, Kobayashi N, Sumida K, Satomora S, Matsuura S, et al. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochem Biophys Acta 2001; 1525: 149-60.
63. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003; 13: 457-70.
64. Isono T, Tanaka T, Kageyama S, Yoshiki T. Structural diversity of cancer-related and non-cancer related prostate-specific antigen. Clin Chem 2002; 48: 2187-94.
65. Tanaka T, Isono T, Yoshiki T, Yuasa T, Okada Y. A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Res 2000; 60: 56-9.
66. Sumi S, Arai K, Kitahara S, Yoshida K. Serial affinity chromatography demonstrates altered asparagine linked sugar chain structures of prostate-specific antigen in human prostate carcinoma. J Chromatogr B Biomed Sci Appl 1999; 727: 9-14.
67. Ohyama C, Hosono M, Nitta K, Oheda M, Yoshikawa K, Habuchi T, et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004; 14 (8): 671-9.
68. Janković MM, Kosanović MM. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem 2005; 38: 58-65.
69. Tabares G, Radcliffe CM, Barrabes S, Ramirez M, Aleixandre N, Hoesel W, et al. Different glycan structures in prostate specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006; 16(2): 132-45.
70. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, et al. Precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60: 756-9.
71. Wang TJ, Slawin KM, Rittenhouse HG, Millar LS, Mikolajczyk SD. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem 2000; 267: 4040-4045.
72. Barak M, Mecz Y, Lurie A, Gruener N. Binding of serum prostate antigen to concanavalin A in patients with cancer or hyperplasia of the prostate. Oncology 1989; 46: 375-7.
73. Basu PS, Majhi R, Batabyal SK. Lectin and serum-PSA interaction as a screening test for prostate cancer. Clin Biochem 2003; 36: 373-6.
74. Kosanović MM, Janković MM. Sialylation and fucosylation of cancer-associated prostate specific antigen. JBUON 2005; 10: 247-50.
75. Kosanović M, Janković M. Molecular forms of human prostate-specific antigen in urine of subjects with benign prostatic hyperplasia. Arch Biol Sci 2006; 58 (2): 77-82.
76. Takahashi T, Ikeda Y, Miyoshi E, Yaginuma Y, Ishikawa M, Taniguchi N. Alpha 1,6 fucosyltransferase is highly and specifically expressed in human ovarian serous adenocarcinomas. Int J Cancer 2000; 88 (6): 914-9.
77. Turner GA, Goodarzi MT, Thompson S. Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconj J 1995; 12 (3): 211-8.
78. Wang PH, Lee WL, Juang CM, Yang YH, Lo WH, Lai CR, et al. Altered mRNA expressions of sialyltransfreases in ovarian cancers. Gynecol Oncol 2005; 99 (3): 631-9.
79. Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO blood groups. J Epidemiol Community Health 1993; 47 (4): 287-9.
80. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 1994; 25 (4): 364-72.
81. Casey RC, Oegema TR, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz AP. Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 2003; 20 (2): 143-52.
82. Nozawa S, Yajima M, Sakuma T, Udagawa Y, Kiguchi K, Sakayori M, et al. Cancer-associated galactosyltransferase as a new marker for ovarian clear cell carcinoma. Cancer Res 1990; 50 (3): 754-9.
83. Gercel-Taylor C, Bazzet LB, Taylor DD. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 2001; 81 (1): 71-6.
84. Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004; 40: 2604-12.
85. Janković M. Cancer antigen 125: biochemical properties and diagnostic significance. Jugoslov Med Biohem 2001; 20: 201-6.
86. Janković M, Milutinović B. Pregnancy-associated ca125 antigen as mucin: evaluation of ferning morphology. Mol Hum Reprod 2007; 13 (6): 405-8.
87. Bast RCJr, Feenney M, Lazarus M, Nadler LM, Colvin RC, Knapp RC. Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
88. Nustad K, Lebedin Y, Lloyd KO, Shigemasa K, de Bruijn HWA, Jansson B, et al. Epitopes on CA125 from cervical mucus and ascites fluid and characterization of six new antibodies. Tumor Biol 2002; 23: 303-14.
89. Lloyd KO, Yin BWT Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3. Tumor Biol 2001; 22 (2): 77-82.
90. Nagata A, Hirota N, Sakai T, Fujimoto M, Komoda T Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen. Tumor Biol 1991; 22: 348-66.
91. Yin BWT, Loyd KO. Molecular cloning of the CA125 ovarian cancer antigen. J Biol Chem 2001; 276: 27371-5.
92. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA125 gene: An extracellular super-structure dominated by repeat sequences. Tumor Biol 2001; 22: 348-66.
93. Hansen JE, Lund O, Engelbrecht J, Bohr H, Nielsen JO, Hensen J-E. Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase. Biochem J 1995; 338: 801-13.
94. Lloyd KO, Yin BWT, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int J Cancer 1997; 71: 842-50.
95. Davis HM, Zuwarski VR Jr, Bast RC Jr, Klug TL. Characterization of the CA125 antigen associated with human epithelial ovarian carcinoms. Cancer Res 1986; 46: 6143-8.
96. Wong NK, Easton RL, Pancio M, Sutton-Smith M, Morrison JC, Lattanzio FA, et al. Characterization of the oligosaccharides associated with human ovarian tumor marker CA125. J Biol Chem 2003; 278: 28619-34.
97. Janković M, Tapušković B. Molecular forms and microheterogeneity of oligosaccharide chains of pregnancyassociated CA125 antigen. Hum Rep 2005; 20: 2632-8.
98. Milutinović B, Janković M. Analysis of the protein and glycan parts of ca125 antigen from human amniotic fluid. Arch Biol Sci 2007; 59 (2): 97-103.
99. Janković M, Milutinović B. Glycoforms of CA125 antigen as possible cancer biomarker. Cancer Biomark 2008; 1: 1- 8.
100. Wallach J, eds. Interpretation of diagnostic test. 7th ed. Philadelphia: Lipppincott Williams&Wilkins; 2000: 1026.
101. Montz FJ. CA 125. In: Sell S, ed. Serological cancer markers. PLACE: Humana Press; 1992: 417-25.
102. Janković M, Kosanović M, Hajduković- Dragojlović Lj, Golubović S. Development of immunoradiometric assay for quantitative determination of free prostate-specific antigen. Jugoslov Med Biohem 2005; 24 (2): 129-134.
103. Consortium for functional glycomics. (Online). Available from URL: http://www.functionalglycomics.org
104. Hirabayashi J, Arata Y, Kasai K. Glycome project: Concept, strategy and preliminary application to Caenorhabditis elegans. Proteomics 2001; 1: 295-303.
105. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated approach to structure-function relationships of glycans. Nat Methods 2005; 2 (11): 817-24.
106. Hirabayashi J. Lectin-based structural glycomcs: glycoproteomics and glycan binding. Glycoconj J 2004; 21: 35-40.
107. Campbell C, Yarema KJ. Large-scale approaches for glycobiology. Genome Biol 2005; 6 (11): 236.